{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:27:52Z","timestamp":1790015272175,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40273-025-01534-8","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:28:51Z","timestamp":1758979731000},"page":"1389-1403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Economic Burden of Inflammatory Arthritis: A Systematic Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-6684","authenticated-orcid":false,"given":"Xiaoyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2795-4705","authenticated-orcid":false,"given":"Jiaru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0836-5349","authenticated-orcid":false,"given":"Zhengwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7943-077X","authenticated-orcid":false,"given":"Sumeet","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-3998","authenticated-orcid":false,"given":"Huajie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"1534_CR1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","volume":"352","author":"D McGonagle","year":"1998","unstructured":"McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352:1137\u201340.","journal-title":"Lancet"},{"key":"1534_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/1354750X.2020.1794043","volume":"26","author":"B Kolarz","year":"2021","unstructured":"Kolarz B, Podgorska D, Podgorski R. Insights of rheumatoid arthritis biomarkers. Biomarkers. 2021;26:185\u201395.","journal-title":"Biomarkers"},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","volume":"73","author":"MM Schoels","year":"2014","unstructured":"Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73:238\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1534_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/annrheumdis-2019-216243","volume":"79","author":"P-H Hsieh","year":"2020","unstructured":"Hsieh P-H, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020;79:771\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1534_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/bmj.320.7245.1335","volume":"320","author":"S Byford","year":"2000","unstructured":"Byford S. Economic note: cost of illness studies. BMJ. 2000;320:1335.","journal-title":"BMJ"},{"key":"1534_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","volume":"36","author":"LS D\u2019Angiolella","year":"2018","unstructured":"D\u2019Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. Pharmacoeconomics. 2018;36:567\u201389.","journal-title":"Pharmacoeconomics"},{"key":"1534_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-024-01428-1","volume":"42","author":"IC Antonazzo","year":"2024","unstructured":"Antonazzo IC, Gribaudo G, La Vecchia A, Ferrara P, Piraino A, Cortesi PA, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: an updated systematic literature review. Pharmacoeconomics. 2024;42:1329\u201343.","journal-title":"Pharmacoeconomics"},{"issue":"4 Suppl. 73","key":"1534_CR8","first-page":"S126","volume":"30","author":"PA Cortesi","year":"2012","unstructured":"Cortesi PA, Scalone L, D\u2019Angiolella L, Belisari A, Fusco F, Olivieri I, et al. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl. 73):S126\u201331.","journal-title":"Clin Exp Rheumatol"},{"key":"1534_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","volume":"107","author":"R Burgos-Pol","year":"2016","unstructured":"Burgos-Pol R, Mart\u00ednez-Sesmero JM, Ventura-Cerd\u00e1 JM, El\u00edas I, Caloto MT, Casado M\u00c1. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107:577\u201390.","journal-title":"Actas Dermosifiliogr"},{"issue":"4 Suppl. 73","key":"1534_CR10","first-page":"S136","volume":"30","author":"I Palla","year":"2012","unstructured":"Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, et al. A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol. 2012;30(4 Suppl. 73):S136\u201341.","journal-title":"Clin Exp Rheumatol"},{"key":"1534_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327.","journal-title":"Clin Mol Hepatol"},{"key":"1534_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653\u201371.","journal-title":"Pharmacoeconomics"},{"key":"1534_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700.","journal-title":"BMJ"},{"key":"1534_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2012.03.005","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012. https:\/\/doi.org\/10.1016\/j.jocd.2012.03.005.","journal-title":"Biochem Med"},{"key":"1534_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6:51\u20139.","journal-title":"Evid Policy"},{"key":"1534_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","volume":"12","author":"M Drummond","year":"2009","unstructured":"Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12:409\u201318.","journal-title":"Value Health"},{"key":"1534_CR17","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.4330","volume":"30","author":"JM Lachin","year":"2011","unstructured":"Lachin JM. Power and sample size evaluation for the Cochran\u2013Mantel\u2013Haenszel mean score (Wilcoxon rank sum) test and the Cochran-Armitage test for trend. Stat Med. 2011;30:3057\u201366.","journal-title":"Stat Med"},{"key":"1534_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3899\/jrheum.141277","volume":"42","author":"N Tsifetaki","year":"2015","unstructured":"Tsifetaki N, Migkos MP, Papagoras C, Voulgari PV, Athanasakis K, Drosos AA. Counting costs under severe financial constraints: a cost-of-illness analysis of spondyloarthropathies in a tertiary hospital in Greece. J Rheumatol. 2015;42:963\u20137.","journal-title":"J Rheumatol"},{"key":"1534_CR19","doi-asserted-by":"publisher","first-page":"15385","DOI":"10.1038\/s41598-023-42623-y","volume":"13","author":"BS Bagepally","year":"2023","unstructured":"Bagepally BS, Kumar SS, Sasidharan A, Haridoss M, Venkataraman K. Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India. Sci Rep. 2023;13:15385.","journal-title":"Sci Rep"},{"issue":"5","key":"1534_CR20","first-page":"661","volume":"32","author":"L Tu","year":"2014","unstructured":"Tu L, Rai JC, Cao S, Lin Z, Hu Z, Gu J. Costs and work limitation of patients with ankylosing spondylitis in China. Clin Exp Rheumatol. 2014;32(5):661\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00296-023-05282-w","volume":"43","author":"F Koster","year":"2023","unstructured":"Koster F, Bakx PLH, Kok MR, Barreto DL, Weel-Koenders AEAM. Multimorbidity status and annual healthcare expenditures of rheumatoid arthritis patients: a Dutch hospital-centered versus population-based comparison. Rheumatol Int. 2023;43(6):1067\u201376.","journal-title":"Rheumatol Int"},{"key":"1534_CR22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00296-012-2542-x","volume":"33","author":"A Pet\u0159\u00edkov\u00e1","year":"2013","unstructured":"Pet\u0159\u00edkov\u00e1 A, Dole\u017eal T, Klime\u0161 J, Vocelka M, \u0160edov\u00e1 L, Kol\u00e1\u0159 J. The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Rheumatol Int. 2013;33:1813\u20139.","journal-title":"Rheumatol Int"},{"key":"1534_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40261-016-0491-y","volume":"37","author":"FS Mennini","year":"2017","unstructured":"Mennini FS, Marcellusi A, Gitto L, Iannone F. Economic burden of rheumatoid arthritis in Italy: possible consequences on anti-citrullinated protein antibody-positive patients. Clin Drug Investig. 2017;37:375\u201386.","journal-title":"Clin Drug Investig"},{"key":"1534_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbspin.2009.11.007","volume":"77","author":"M Younes","year":"2010","unstructured":"Younes M, Jalled A, Aydi Z, Zrour S, Korbaa W, Ben Salah Z, et al. Socioeconomic impact of ankylosing spondylitis in Tunisia. Joint Bone Spine. 2010;77:41\u20136.","journal-title":"Joint Bone Spine"},{"key":"1534_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00252.x","volume":"11","author":"G Kobelt","year":"2008","unstructured":"Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E. The burden of ankylosing spondylitis in Spain. Value Health. 2008;11:408\u201315.","journal-title":"Value Health"},{"key":"1534_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283865","volume":"18","author":"E Schorling","year":"2023","unstructured":"Schorling E, Lick S, Steinberg P, Br\u00fcggemann DA. Health care utilizations and costs of Campylobacter enteritis in Germany: a claims data analysis. PLoS ONE. 2023;18: e0283865.","journal-title":"PLoS ONE"},{"key":"1534_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.rbr.2015.06.002","volume":"56","author":"VF Azevedo","year":"2016","unstructured":"Azevedo VF, Rossetto CN, Lorencetti PG, Tramontin MY, Fornazari B, Ara\u00fajo DV. Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system. Revista Brasileira de Reumatologia (Engl Ed). 2016;56:131\u20137.","journal-title":"Revista Brasileira de Reumatologia (Engl Ed)"},{"key":"1534_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1136\/ard.2005.046367","volume":"65","author":"D Huscher","year":"2006","unstructured":"Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65:1175\u201383.","journal-title":"Ann Rheum Dis"},{"key":"1534_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/ard.62.8.741","volume":"62","author":"A Boonen","year":"2003","unstructured":"Boonen A. Costs of ankylosing spondylitis in three European countries: the patient\u2019s perspective. Ann Rheum Dis. 2003;62:741\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1534_CR30","first-page":"1008","volume":"28","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, et al. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2022;28:1008\u201320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1534_CR31","first-page":"490","volume":"28","author":"TM Torres","year":"2010","unstructured":"Torres TM, Ferraz MB, Ciconelli RM. Resource utilisation and cost of ankylosing spondylitis in Brazil. Clin Exp Rheumatol. 2010;28(4):490\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1534_CR32","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","volume":"38","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, Von Hin\u00fcber U, Meier F, Tian H, B\u00f6hm K, Jugl SM, et al. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int. 2018;38:2121\u201331.","journal-title":"Rheumatol Int"},{"key":"1534_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00296-009-0936-1","volume":"30","author":"V Brodszky","year":"2009","unstructured":"Brodszky V, B\u00e1lint P, G\u00e9her P, Hodinka L, Horv\u00e1th G, Ko\u00f3 \u00c9, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int. 2009;30:199\u2013205.","journal-title":"Rheumatol Int"},{"key":"1534_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5114\/reum.2016.64902","volume":"54","author":"F Raciborski","year":"2016","unstructured":"Raciborski F, \u015aliwczy\u0144ski A, K\u0142ak A, Kwiatkowska B, Brzozowska M, T\u0142ustochowicz M. Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system: the case of Poland. Rheumatology. 2016;54:278\u201384.","journal-title":"Rheumatology"},{"key":"1534_CR35","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1007\/s10067-021-05713-8","volume":"40","author":"JF Merola","year":"2021","unstructured":"Merola JF, Dennis N, Chakravarty SD, Villacorta R, Mesana L, Lin I, et al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA\u2014a retrospective study of claims data from 2009 to 2020. Clin Rheumatol. 2021;40:4061\u201370.","journal-title":"Clin Rheumatol"},{"key":"1534_CR36","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3899\/jrheum.090988","volume":"37","author":"TY Zhu","year":"2010","unstructured":"Zhu TY, Tam L-S, Leung Y-Y, Kwok L-W, Wong K-C, Yu T, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol. 2010;37:1214\u201320.","journal-title":"J Rheumatol"},{"key":"1534_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2278-0","volume":"17","author":"SR Feldman","year":"2017","unstructured":"Feldman SR, Tian H, Gilloteau I, Mollon P, Shu M. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective US database. BMC Health Serv Res. 2017;17: 337.","journal-title":"BMC Health Serv Res"},{"key":"1534_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.150406","volume":"43","author":"S L\u00f6fvendahl","year":"2016","unstructured":"L\u00f6fvendahl S, Petersson IF, Theander E, Svensson \u00c5, Zhou C, Steen Carlsson K. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in southern Sweden: is it all psoriasis-attributable morbidity? J Rheumatol. 2016;43:640\u20137.","journal-title":"J Rheumatol"},{"key":"1534_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/03009740310003703","volume":"32","author":"M S\u00f6derlin","year":"2003","unstructured":"S\u00f6derlin M, Kautiainen H, Jonsson D, Skogh T, Leirisalo-Repo M. The costs of early inflammatory joint disease: a population-based study in southern Sweden. Scand J Rheumatol. 2003;32:216\u201324.","journal-title":"Scand J Rheumatol"},{"key":"1534_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/03009742.2020.1750688","volume":"49","author":"M Husberg","year":"2020","unstructured":"Husberg M, Bernfort L, Hallert E. Presence of anti-citrullinated protein antibodies and costs and disease activity in early rheumatoid arthritis\u2014a 3-year follow-up. Scand J Rheumatol. 2020;49:379\u201388.","journal-title":"Scand J Rheumatol"},{"key":"1534_CR41","first-page":"469","volume":"25","author":"J An","year":"2019","unstructured":"An J, Bider-Canfield Z, Kang J, Alemao E, Connolly SE, Lin AT, et al. Economic evaluation of nticyclic citrullinated peptide positivity in rheumatoid arthritis. J Manag Care Spec Pharm. 2019;25:469\u201377.","journal-title":"J Manag Care Spec Pharm"},{"key":"1534_CR42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.semarthrit.2019.11.007","volume":"50","author":"H Kim","year":"2020","unstructured":"Kim H, Cho S-K, Kim JW, Jung S-Y, Jang EJ, Bae S-C, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 2020;50:526\u201333.","journal-title":"Semin Arthritis Rheum"},{"key":"1534_CR43","first-page":"4","volume":"24","author":"J Shafrin","year":"2018","unstructured":"Shafrin J, Tebeka MG, Price K, Patel C, Michaud K. The economic burden of ACPA-positive status among patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2018;24:4\u201311.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1534_CR44","first-page":"289","volume":"33","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol. 2006;33(2):289\u201395.","journal-title":"J Rheumatol"},{"key":"1534_CR45","doi-asserted-by":"publisher","first-page":"1221393","DOI":"10.3389\/fmed.2023.1221393","volume":"10","author":"Y-M Chiu","year":"2023","unstructured":"Chiu Y-M, Lan J-L, Huang W-L, Wu C-S. Estimation of life expectancy and healthcare cost in rheumatoid arthritis patients with and without depression: a population-based retrospective cohort study. Front Med. 2023;10:1221393.","journal-title":"Front Med"},{"key":"1534_CR46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/acr2.11376","volume":"4","author":"RK Dore","year":"2022","unstructured":"Dore RK, Antonova JN, Burudpakdee C, Chang L, Gorritz M, Genovese MC. The incidence, prevalence, and associated costs of anemia, malignancy, venous thromboembolism, major adverse cardiovascular events, and infections in rheumatoid arthritis patients by treatment history in the United States. ACR Open Rheumatol. 2022;4:473\u201382.","journal-title":"ACR Open Rheumatol"},{"key":"1534_CR47","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1007\/s10067-019-04613-2","volume":"38","author":"J An","year":"2019","unstructured":"An J, Nyarko E, Hamad MA. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38:2717\u201326.","journal-title":"Clin Rheumatol"},{"key":"1534_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002454","volume":"8","author":"P-H Hsieh","year":"2022","unstructured":"Hsieh P-H, Geue C, Wu O, McIntosh E, Siebert S. How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis? RMD Open. 2022;8: e002454.","journal-title":"RMD Open"},{"key":"1534_CR49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, et al. Rheumatoid arthritis: interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46:360\u20139.","journal-title":"J Rheumatol"},{"key":"1534_CR50","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/13696998.2019.1572015","volume":"22","author":"N Li","year":"2019","unstructured":"Li N, Chan E, Peterson S. The economic burden of depression among adults with rheumatoid arthritis in the United States. J Med Econ. 2019;22:372\u20138.","journal-title":"J Med Econ"},{"key":"1534_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41927-020-0115-2","volume":"4","author":"DP Hudesman","year":"2020","unstructured":"Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, et al. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol. 2020;4:16.","journal-title":"BMC Rheumatol"},{"key":"1534_CR52","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/rheumatology\/kes074","volume":"51","author":"MK Kvamme","year":"2012","unstructured":"Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology. 2012;51:1618\u201327.","journal-title":"Rheumatology"},{"key":"1534_CR53","unstructured":"Vassall A, Sweeney S, Kahn JG, Gomez G, Bollinger L, Marseille E, et al. Reference case for estimating the costs of global health services and interventions. 2017:91. https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/4653001."},{"key":"1534_CR54","doi-asserted-by":"crossref","unstructured":"Arul Prakasam KC, Athmaja Krishna PS, Aleena S, Aslam A. A comparative study on pharmacoeconomic analysis of rheumatoid arthritis patient in two different hospitals in Tamil Nadu. Int J Pharm Pharm Sci. 2020;12(2):104\u20137.","DOI":"10.22159\/ijpps.2020v12i2.35935"},{"key":"1534_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3346\/jkms.2014.29.2.190","volume":"29","author":"T-J Lee","year":"2014","unstructured":"Lee T-J, Park B-H, Kim JW, Shin K, Lee EB, Song Y-W. Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea. J Korean Med Sci. 2014;29:190.","journal-title":"J Korean Med Sci"},{"key":"1534_CR56","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00296-015-3236-y","volume":"35","author":"N Akko\u00e7","year":"2015","unstructured":"Akko\u00e7 N, Direskeneli H, Erdem H, G\u00fcl A, Kabasakal Y, Kiraz S, et al. Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. Rheumatol Int. 2015;35:1473\u20138.","journal-title":"Rheumatol Int"},{"key":"1534_CR57","doi-asserted-by":"publisher","DOI":"10.2174\/17450179-v19-e230510-2022-34","volume":"19","author":"F Parlindungan","year":"2023","unstructured":"Parlindungan F, Hidayat R, Ariane A, Shatri H. Association between proinflammatory cytokines and anxiety and depression symptoms in rheumatoid arthritis patients: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2023;19: e174501792304261.","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"1534_CR58","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1093\/rheumatology\/ket169","volume":"52","author":"F Matcham","year":"2013","unstructured":"Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013;52:2136\u201348.","journal-title":"Rheumatology"},{"key":"1534_CR59","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.semarthrit.2017.10.009","volume":"47","author":"E Alemao","year":"2018","unstructured":"Alemao E, Guo Z, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: a patient registry study. Semin Arthritis Rheum. 2018;47:630\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"1534_CR60","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1534_CR61","doi-asserted-by":"publisher","first-page":"1759720X2110248","DOI":"10.1177\/1759720X211024830","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Cho S-K, Choi S, Im SG, Jung S-Y, Jang EJ, et al. Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X2110248.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"1534_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/14737167.2016.1126513","volume":"16","author":"T Lo","year":"2016","unstructured":"Lo T, Parkinson L, Cunich M, Byles J. Cost of arthritis: a systematic review of methodologies used for direct costs. Expert Rev Pharmacoecon Outcomes Res. 2016;16:51\u201365.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1534_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/09733698241239709","author":"O Bali","year":"2024","unstructured":"Bali O, Singla S. X cost of illness and out-of-pocket expenditure of ankylosing spondylitis and rheumatoid arthritis at a tertiary care hospital in North India using conventional disease-modifying antirheumatic drugs. Indian J Rheumatol. 2024. https:\/\/doi.org\/10.1177\/09733698241239709.","journal-title":"Indian J Rheumatol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01534-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:03:07Z","timestamp":1762776187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01534-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01534-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"3 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xiaoyu Zhang, Jiaru Liu, Zhengwei Wang, James Galloway, Sam Norton, Sumeet Singla and Huajie Jin have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"XZ, HJ, SN and JG were involved in the study concept and design. XZ, JL and ZW carried out sifting and data extraction. XZ drafted the initial manuscript. Critical revisions of the manuscript for important intellectual content were performed by HJ, JG, SN and SS. XZ has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}